Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17202204 | 0.88 | MAP4K4 (0.39) | — | |
| SCHEMBL31541398 | 0.80 | KDM4E (0.38) | ACACB | |
| SCHEMBL22032079 | 0.79 | AOC3 (0.33) | ACACBHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17202235 | 0.77 | ACACB (0.38) | ACACBRBP4HDAC3HDAC4HDAC1 | |
| SCHEMBL17202082 | 0.77 | RBP4 (0.36) | RBP4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18539060 | 0.77 | CHRM4 (0.32) | ACACB | |
| SCHEMBL17202001 | 0.77 | — | — | |
| SCHEMBL18128074 | 0.75 | MTOR (0.31) | — | |
| SCHEMBL22084736 | 0.75 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20605945 | 0.73 | CHRM4 (0.35) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3134410-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPA1, TRPV1, TRPV2 | ACACB 4284/4885RBP4 4182/4885HDAC3 2122/4885 |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPA1, TRPV1, TRPV2 | ACACB 4284/4885RBP4 4182/4885HDAC3 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.